Off-campus UMass Amherst users: To download campus access dissertations, please use the following link to log into our proxy server with your UMass Amherst user name and password.
Non-UMass Amherst users: Please talk to your librarian about requesting this dissertation through interlibrary loan.
Dissertations that have an embargo placed on them will not be available to anyone until the embargo expires.
Author ORCID Identifier
Campus-Only Access for One (1) Year
Doctor of Philosophy (PhD)
Molecular and Cellular Biology
Year Degree Awarded
Month Degree Awarded
Biochemistry | Molecular Biology | Structural Biology
Human lysosomal neuraminidase 1 (hNEU1) is an exo-a-sialidase which cleaves a(2-3) and a(2-6) linked sialic acids on glycoproteins in the lysosome. Deficiency of hNEU1 in the lysosome results in sialidosis, a lysosomal storage disease. Currently there is no effective treatment for sialidosis, which leads to a rising interest in discovering potential therapies. Here we presented a small molecule, α-D-N-acetylneuraminic acid (NANA), increases the protein amount and activity of both wild-type hNEU1 and three different hNEU1 mutations found in sialidosis patients in our mammalian cell system, suggesting that NANA works as a potential pharmacological chaperone for hNEU1 and provides a good scaffold for the development of pharmacological chaperone therapy for sialidosis. We also compared NANA with two potential treatments for sialidosis using MG132, a small molecule proteostasis regulator, or lysosomal protective protein/cathepsin A (PPCA), an auxiliary protein for hNEU1, and demonstrated that using MG132 or PPCA with NANA as potential combined treatments for sialidosis can enhance the enzymatic activity of hNEU1 in mammalian cells.
Chu, Di, "PHARMACOLOGICAL CHAPERONING OF HUMAN LYSOSOMAL NEURAMINIDASE 1" (2021). Doctoral Dissertations. 2170.